Evonik can initiate the development of long-acting microparticle products for the delivery of siRNA delivery through feasibility assessments and proof-of-concept studies. Delivery of siRNA can be extended for 6 months. With experience formulating nucleic acids with bioabsorbable polymer excipients, Evonik provides the drug delivery expertise needed to evaluate formulation approaches, mitigate development risks, and accelerate progress toward successful long-acting drug delivery solutions.
Typical Applications
Long-acting injectable PLG drug products are the dominant polymer platform for controlled-release parenteral medications. They are primarily used to treat chronic diseases requiring long-term adherence, providing stable drug delivery over weeks to months and eliminating the need for daily oral dosing or if oral dosing is not possible which is often the case for bilogicals like proteins and nucleic acids.
Long-acting injecatable PLG drug products, like microparticles, can be administered locally to achieve local delivery to tumors and other sites.
Long-acting injecatable PLG drug products, like microparticles, can be administered locally to achieve local delivery to tumors and other sites.
Benefits at a glance
- Experience: Evonik's formulation experience and drug delivery technologies come from providing formulation services and innovation for 50+ years.
- Proven: Market-tested microparticle dosage forms.
- Versatile: Enables systemic and local delivery of siRNA to tumors.
- Efficacy: Extends the duration of siRNA exposure to 6+ months.
- Safe: Uses biocompatible, bioabsorbable RESOMER® and LACTEL® polymers.
- Trusted: Lactide/glycolide polymers are used in 60+ approved products.